Published in Cell Microbiol on September 25, 2012
Temporal analysis of hepatitis C virus cell entry with occludin directed blocking antibodies. PLoS Pathog (2013) 1.08
Claudin-2 pore function requires an intramolecular disulfide bond between two conserved extracellular cysteines. Am J Physiol Cell Physiol (2013) 0.86
CD81 and hepatitis C virus (HCV) infection. Viruses (2014) 0.84
CD81-receptor associations--impact for hepatitis C virus entry and antiviral therapies. Viruses (2014) 0.83
Interaction of human tumor viruses with host cell surface receptors and cell entry. Viruses (2015) 0.78
Super-resolution microscopy: a virus' eye view of the cell. Viruses (2014) 0.78
Production, purification and characterization of recombinant, full-length human claudin-1. PLoS One (2013) 0.78
Claudins in viral infection: from entry to spread. Pflugers Arch (2016) 0.75
Basic local alignment search tool. J Mol Biol (1990) 659.07
Dictionary of protein secondary structure: pattern recognition of hydrogen-bonded and geometrical features. Biopolymers (1983) 99.69
T-Coffee: A novel method for fast and accurate multiple sequence alignment. J Mol Biol (2000) 57.88
Database resources of the National Center for Biotechnology Information. Nucleic Acids Res (2007) 22.53
Binding of hepatitis C virus to CD81. Science (1998) 12.40
Reduced surface: an efficient way to compute molecular surfaces. Biopolymers (1996) 10.62
Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature (2007) 9.52
Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci U S A (2003) 8.21
Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature (2009) 8.05
The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J (2002) 7.93
Tetraspanin functions and associated microdomains. Nat Rev Mol Cell Biol (2005) 6.22
EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med (2011) 6.21
Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81. J Virol (1999) 4.99
Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nat Med (2012) 3.89
Tools for comparative protein structure modeling and analysis. Nucleic Acids Res (2003) 3.68
Photobleaching-corrected FRET efficiency imaging of live cells. Biophys J (2004) 3.41
A genetically humanized mouse model for hepatitis C virus infection. Nature (2011) 3.15
Formation of tight junction: determinants of homophilic interaction between classic claudins. FASEB J (2007) 2.43
Diverse CD81 proteins support hepatitis C virus infection. J Virol (2006) 2.07
CD81 extracellular domain 3D structure: insight into the tetraspanin superfamily structural motifs. EMBO J (2001) 1.90
Inhibition of hepatitis C virus infection by anti-claudin-1 antibodies is mediated by neutralization of E2-CD81-claudin-1 associations. Hepatology (2010) 1.87
Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo. Hepatology (2008) 1.82
Protein-protein interactions in the tetraspanin web. Physiology (Bethesda) (2005) 1.79
The cell biology of receptor-mediated virus entry. J Cell Biol (2011) 1.75
The HIV-1 DNA flap stimulates HIV vector-mediated cell transduction in the brain. Nat Biotechnol (2001) 1.75
Hepatitis C virus cell entry: role of lipoproteins and cellular receptors. J Gen Virol (2009) 1.72
Claudin association with CD81 defines hepatitis C virus entry. J Biol Chem (2010) 1.67
Clathrin- and caveolin-independent entry of human papillomavirus type 16--involvement of tetraspanin-enriched microdomains (TEMs). PLoS One (2008) 1.63
CD81 and claudin 1 coreceptor association: role in hepatitis C virus entry. J Virol (2008) 1.62
Identification of the hepatitis C virus E2 glycoprotein binding site on the large extracellular loop of CD81. J Virol (2002) 1.58
Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes. Gastroenterology (2010) 1.58
Stoichiometry and assembly of olfactory cyclic nucleotide-gated channels. Neuron (2004) 1.56
Docking essential dynamics eigenstructures. Proteins (2005) 1.45
Pathophysiological mechanisms of dominant and recessive GLRA1 mutations in hyperekplexia. J Neurosci (2010) 1.33
A novel cysteine cross-linking method reveals a direct association between claudin-1 and tetraspanin CD9. Mol Cell Proteomics (2007) 1.30
Epithelial Na+ channel subunit stoichiometry. Biophys J (2005) 1.24
Hepatitis C virus entry: beyond receptors. Rev Med Virol (2012) 1.23
Residues in a highly conserved claudin-1 motif are required for hepatitis C virus entry and mediate the formation of cell-cell contacts. J Virol (2009) 1.19
Biskit--a software platform for structural bioinformatics. Bioinformatics (2007) 1.19
Complete predicted three-dimensional structure of the facilitator transmembrane protein and hepatitis C virus receptor CD81: conserved and variable structural domains in the tetraspanin superfamily. Biophys J (2006) 1.18
Hepatitis C virus induces CD81 and claudin-1 endocytosis. J Virol (2012) 1.14
Engagement of CD81 induces ezrin tyrosine phosphorylation and its cellular redistribution with filamentous actin. J Cell Sci (2009) 1.05
Hepatocyte permissiveness to Plasmodium infection is conveyed by a short and structurally conserved region of the CD81 large extracellular domain. PLoS Pathog (2008) 1.05
Molecular modelling of the emergence of azole resistance in Mycosphaerella graminicola. PLoS One (2011) 0.99
Determinants of CD81 dimerization and interaction with hepatitis C virus glycoprotein E2. Biochem Biophys Res Commun (2005) 0.97
Biophysical properties of 9 KCNQ1 mutations associated with long-QT syndrome. Circ Arrhythm Electrophysiol (2009) 0.95
Strategies for targeting tetraspanin proteins: potential therapeutic applications in microbial infections. BioDrugs (2009) 0.90
Structural characterization of recombinant human CD81 produced in Pichia pastoris. Protein Expr Purif (2007) 0.85
The C-terminal tail of tetraspanin protein CD9 contributes to its function and molecular organization. J Cell Sci (2011) 0.81
Fine architecture and mutation mapping of human brain inhibitory system ligand gated ion channels by high-throughput homology modeling. Adv Protein Chem Struct Biol (2010) 0.80
Complete replication of hepatitis C virus in cell culture. Science (2005) 18.59
Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J Virol (2002) 11.99
Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature (2007) 9.52
Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci U S A (2003) 8.21
EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med (2011) 6.21
Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med (2007) 6.05
Efficient replication of hepatitis C virus genotype 1a RNAs in cell culture. J Virol (2003) 3.84
Time- and temperature-dependent activation of hepatitis C virus for low-pH-triggered entry. J Virol (2006) 3.71
Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. Proc Natl Acad Sci U S A (2006) 3.69
CD81 is required for hepatitis C virus glycoprotein-mediated viral infection. J Virol (2004) 3.53
Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology (2006) 3.44
Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR. J Virol (2003) 3.10
Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies. Hepatology (2008) 3.09
Persistent hepatitis C virus infection in vitro: coevolution of virus and host. J Virol (2006) 2.77
Initiation of hepatitis C virus infection is dependent on cholesterol and cooperativity between CD81 and scavenger receptor B type I. J Virol (2006) 2.65
Hepatitis C virus infects the endothelial cells of the blood-brain barrier. Gastroenterology (2011) 2.51
Oseltamivir compared with the Chinese traditional therapy maxingshigan-yinqiaosan in the treatment of H1N1 influenza: a randomized trial. Ann Intern Med (2011) 2.47
Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency. J Clin Microbiol (2006) 2.45
Hepatitis C virus receptor expression in normal and diseased liver tissue. Hepatology (2008) 2.43
Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission. AIDS (2006) 2.23
Diverse CD81 proteins support hepatitis C virus infection. J Virol (2006) 2.07
Discordant role of CD4 T-cell response relative to neutralizing antibody and CD8 T-cell responses in acute hepatitis C. Gastroenterology (2006) 2.05
Oxidized low-density lipoprotein inhibits hepatitis C virus cell entry in human hepatoma cells. Hepatology (2006) 2.04
Multiple effects of silymarin on the hepatitis C virus lifecycle. Hepatology (2010) 1.92
Inhibition of hepatitis C virus infection by anti-claudin-1 antibodies is mediated by neutralization of E2-CD81-claudin-1 associations. Hepatology (2010) 1.87
Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study. Endocr Relat Cancer (2012) 1.76
Molecular characterization of human immunodeficiency virus type 1 and hepatitis C virus in paid blood donors and injection drug users in china. J Virol (2004) 1.76
Superinfection exclusion in cells infected with hepatitis C virus. J Virol (2007) 1.71
Organellar dynamics during the cell cycle of Toxoplasma gondii. J Cell Sci (2008) 1.70
Scavenger receptor BI and BII expression levels modulate hepatitis C virus infectivity. J Virol (2007) 1.68
Claudin association with CD81 defines hepatitis C virus entry. J Biol Chem (2010) 1.67
Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission. J Virol (2010) 1.67
Golgi biogenesis in Toxoplasma gondii. Nature (2002) 1.67
Inferring viral quasispecies spectra from 454 pyrosequencing reads. BMC Bioinformatics (2011) 1.62
CD81 and claudin 1 coreceptor association: role in hepatitis C virus entry. J Virol (2008) 1.62
Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes. Gastroenterology (2010) 1.58
Measuring tubulin content in Toxoplasma gondii: a comparison of laser-scanning confocal and wide-field fluorescence microscopy. Proc Natl Acad Sci U S A (2002) 1.55
Development of the antibody response in acute HIV-1 infection. AIDS (2004) 1.54
Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies. J Virol (2008) 1.48
Paracrine signals from liver sinusoidal endothelium regulate hepatitis C virus replication. Hepatology (2013) 1.47
Polarization restricts hepatitis C virus entry into HepG2 hepatoma cells. J Virol (2009) 1.44
Effect of cell polarization on hepatitis C virus entry. J Virol (2007) 1.41
Overlapping cortical malformations and mutations in TUBB2B and TUBA1A. Brain (2013) 1.40
Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors. J Hepatol (2010) 1.37
HRas signal transduction promotes hepatitis C virus cell entry by triggering assembly of the host tetraspanin receptor complex. Cell Host Microbe (2013) 1.37
IFITM1 is a tight junction protein that inhibits hepatitis C virus entry. Hepatology (2012) 1.36
Hepatitis C virus infection of neuroepithelioma cell lines. Gastroenterology (2010) 1.35
Pathophysiological mechanisms of dominant and recessive GLRA1 mutations in hyperekplexia. J Neurosci (2010) 1.33
Hepatitis C virus (HCV)-specific immune responses of long-term injection drug users frequently exposed to HCV. J Infect Dis (2008) 1.30
Hepatitis C virus envelope glycoprotein immunization of rodents elicits cross-reactive neutralizing antibodies. Vaccine (2007) 1.28
A cluster of cases of human-to-human transmission caused by severe fever with thrombocytopenia syndrome bunyavirus. Int J Infect Dis (2012) 1.27
In vitro selection of a neutralization-resistant hepatitis C virus escape mutant. Proc Natl Acad Sci U S A (2008) 1.25
Renal clearance of gamma-hydroxybutyric acid in rats: increasing renal elimination as a detoxification strategy. J Pharmacol Exp Ther (2005) 1.24
Characterization of infectious retroviral pseudotype particles bearing hepatitis C virus glycoproteins. J Virol (2004) 1.23
Hepatitis C virus entry: beyond receptors. Rev Med Virol (2012) 1.23
Hepatitis C virus infection reduces hepatocellular polarity in a vascular endothelial growth factor-dependent manner. Gastroenterology (2009) 1.17
A short regulatory domain restricts glycerol transport through yeast Fps1p. J Biol Chem (2002) 1.17
Expression and characterization of a minimal hepatitis C virus glycoprotein E2 core domain that retains CD81 binding. J Virol (2007) 1.15
Identification of PhIL1, a novel cytoskeletal protein of the Toxoplasma gondii pellicle, through photosensitized labeling with 5-[125I]iodonaphthalene-1-azide. Eukaryot Cell (2006) 1.15
Hepatitis C virus induces CD81 and claudin-1 endocytosis. J Virol (2012) 1.14
TgMORN1 is a key organizer for the basal complex of Toxoplasma gondii. PLoS Pathog (2010) 1.14
Mutations in hepatitis C virus E2 located outside the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity. J Virol (2009) 1.13